Trade Group Backs Matrixx On Side-Effect Reporting

Law360, New York (August 30, 2010, 3:25 PM EDT) -- A federal appeals court was wrong to rule in a class action against Matrixx Initiatives Inc. that drug companies must inform shareholders of all adverse event reports linked to a drug, a biotechnology industry group has said in an amicus brief to the U.S. Supreme Court.

The group, BayBio, submitted an amicus brief to the high court Friday in support of Matrixx in its appeal of an October ruling by the U.S. Court of Appeals for the Ninth Circuit. The Supreme Court granted certiorari in the...
To view the full article, register now.